On July 15, WuXi Biologics rose 3.66% in regular trading, trading at HK$39.6/share with turnover of HK$254 million. The Life Sciences Tools & Services sector showed broad strength, with JOINN up 13.33%, Insilico Intelligence up 6.22%, Pharmaron up 5.08%, WuXi XDC up 4.10%, and WuXi AppTec up 3.80%.

The rally follows continued positive sentiment after the company announced on July 9 that its MFG8 drug substance production facility successfully passed the U.S. FDA Pre-License Inspection, marking a critical milestone for commercial-scale supply of a potential blockbuster autoimmune therapy. The approval validates the facility's full quality systems and manufacturing processes for global commercialization. UBS recently raised its target price to HK$51.1 while maintaining a Buy rating. Additionally, the company has sustained an active share buyback program, repurchasing approximately HK$99.8 million worth of shares on July 7.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)